Innate Pharma stock tumbles after phase 1 trial data

Innate Pharma (NASDAQ:IPHA) shares dropped 17% after presenting phase 1 trial data for IPH4502, showing a 33% response rate in non-urothelial tumors and 68.4% disease control in urothelial cancer. The company plans further trials in 2027.

Original reporting
Published Nov 18, 2026, 4:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 4:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$IPHA
Bearish
high confidence
Mentioned
$IPHA
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IPHABearishMed
01

Why it matters

The market is reacting to newly disclosed Phase 1 efficacy and safety metrics, including MTD determination, Grade 3+ TEAEs, and objective response rates by tumor subgroup, which can materially alter perceived probability of success and future trial design.

02

Market read

A same-day selloff follows the first detailed Phase 1 readout, making it a near-term catalyst for IPH positioning and volatility around early oncology ADC signals.

03

What to watch

The article notes planned Phase 1 dose optimization in urothelial cancer after enfortumab vedotin, which may shift expectations toward combination sequencing rather than standalone monotherapy outcomes.

Relevance 8/10Novelty 8/10Timing: same-day reaction to Phase 1 data release (Wednesday)

Background

Innate Pharma is developing IPH4502, a Nectin-4-targeting antibody-drug conjugate, and presented initial Phase 1 results at the EORTC-NCI-AACR Symposium.

Company-level read

Ticker impact

$IPHABearishHigh confidence
Context

Innate Pharma shares fell 17% after releasing Phase 1 data for Nectin-4 ADC IPH4502, including MTD 3.6 mg/kg and 33% ORR in non-urothelial tumors.

Expected impact

Likely further downside or high volatility as investors weigh modest early responses against the 43.4% rate of Grade 3+ TEAEs and the limited urothelial response context.

Evidence & confidence

The article reports a same-day 17% drop tied directly to newly released Phase 1 results, with specific efficacy and toxicity metrics that can change perceived risk-benefit for IPH4502.

Market effects

Adds another datapoint for Nectin-4 ADC development and may influence sentiment around early clinical read-through for oncology antibody-drug conjugates.

Limited, primarily affects US-listed biotech sentiment tied to oncology ADCs.

Moderate for global ADC investors, since the data was presented at an international oncology symposium.

Counterpoint

The MTD was set at 3.6 mg/kg with no febrile neutropenia or hematologic DLTs, and the 33% ORR in non-urothelial tumors could be viewed as a signal worth pursuing despite the stock drop.

Key entities

  • Innate Pharma

    NASDAQ-listed developer of the Nectin-4 ADC IPH4502; shares dropped after Phase 1 data release.

  • IPH4502

    Investigational Nectin-4-targeting antibody-drug conjugate evaluated in Phase 1 across advanced solid tumors.

  • EORTC-NCI-AACR Symposium

    Conference where the initial Phase 1 data were presented.

Related articles

$IPHAHighAI 8/10

Why is Innate Pharma stock sliding today?

Innate Pharma (IPH) shares fell 21.1% to $1.05 after presenting Phase 1 clinical data for IPH4502. The drug showed a 33% response rate in non-urothelial tumors but modest results in urothelial cancer, its primary target. BTIG had a $9.00 price target, but the data underwhelmed, leading to a 52-week low of $1.01. The broader market decline also contributed to the sell-off.

$IPHAMedAI 8/10

Innate Pharma SA: Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026

Innate Pharma presented initial Phase 1 data for IPH4502, an investigational Nectin-4-targeting antibody-drug conjugate, at the ENA 2026 symposium. The study showed encouraging tolerability and antitumor activity across multiple tumor types, including urothelial cancer. The maximum tolerated dose was 3.6 mg/kg, with stomatitis as the only dose-limiting toxicity.

$IPHAMed

Innate Pharma stock maintained at Buy by BTIG on pipeline progress

BTIG maintained a Buy rating and $9.00 price target on Innate Pharma (NASDAQ:IPHA) after its Q3 2026 results. The stock trades at $2.87, with a Fair Value of $4.13. Upcoming catalysts include IPH4502 phase 1 data and PACIFIC-9 readout. The company has €96.8 million in cash, covering operations through Q1 2028. Recent developments include a $75 million upfront payment from a partnership with Swedish Orphan Biovitrum.

$AZNMed

AstraZeneca delays PACIFIC-9 lung cancer trial data to H1 2027

Innate Pharma (IPH, IPHA) announced AstraZeneca (AZN) delayed the PACIFIC-9 trial data to H1 2027 from H2 2026, citing the study's event-driven nature. The trial tests durvalumab with monalizumab or oleclumab in Stage III lung cancer. Monalizumab is co-developed by Innate and AZN. Innate Pharma is a clinical-stage biotech listed in Paris and on Nasdaq.